Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Busbee

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Cataract and Refractive Surgery|July 3, 2019
Cost-utility analysis of cataract surgery in the United States for the year 2018Gary C Brown, Melissa M Brown, Brandon G Busbee
Ophthalmology|December 3, 2003
Cost-utility analysis of cataract surgery in the second eyeBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
Retina (Philadelphia, Pa.)|June 26, 2003
CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularizationBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
Ophthalmology|March 5, 2002
Incremental cost-effectiveness of initial cataract surgeryBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
American Journal of Ophthalmology|August 2, 2015
Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular DegenerationCarl D Regillo, Brandon G Busbee, Allen C Ho, et al.
Ophthalmology|August 4, 2004
Bleb-associated endophthalmitis: clinical characteristics and visual outcomesBrandon G Busbee, Franco M Recchia, Richard Kaiser, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 16, 2005
Changing trends in the microbiologic aspects of postcataract endophthalmitisFranco M Recchia, Brandon G Busbee, Robert B Pearlman, et al.
Ophthalmology|November 20, 2013
Cataract surgery cost utility revisited in 2012: a new economic paradigmGary C Brown, Melissa M Brown, Alicia Menezes, et al.
Ophthalmology|January 23, 2016
Reply: To PMID 24246824Gary C Brown, Melissa M Brown, Alicia Menezes, et al.
Retina (Philadelphia, Pa.)|November 26, 2009
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%Jeffrey S Heier, Carl C Awh, Brandon G Busbee, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Cataract and Refractive Surgery|July 3, 2019
Cost-utility analysis of cataract surgery in the United States for the year 2018Gary C Brown, Melissa M Brown, Brandon G Busbee
Ophthalmology|December 3, 2003
Cost-utility analysis of cataract surgery in the second eyeBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
Retina (Philadelphia, Pa.)|June 26, 2003
CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularizationBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
Ophthalmology|March 5, 2002
Incremental cost-effectiveness of initial cataract surgeryBrandon G Busbee, Melissa M Brown, Gary C Brown, et al.
American Journal of Ophthalmology|August 2, 2015
Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular DegenerationCarl D Regillo, Brandon G Busbee, Allen C Ho, et al.
Ophthalmology|August 4, 2004
Bleb-associated endophthalmitis: clinical characteristics and visual outcomesBrandon G Busbee, Franco M Recchia, Richard Kaiser, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 16, 2005
Changing trends in the microbiologic aspects of postcataract endophthalmitisFranco M Recchia, Brandon G Busbee, Robert B Pearlman, et al.
Ophthalmology|November 20, 2013
Cataract surgery cost utility revisited in 2012: a new economic paradigmGary C Brown, Melissa M Brown, Alicia Menezes, et al.
Ophthalmology|January 23, 2016
Reply: To PMID 24246824Gary C Brown, Melissa M Brown, Alicia Menezes, et al.
Retina (Philadelphia, Pa.)|November 26, 2009
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%Jeffrey S Heier, Carl C Awh, Brandon G Busbee, et al.
Pageof 3